This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (96)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

WILLIAM J. SCHNEIDER, MD; E. LOVELL BECKER, MD

Arch Intern Med. 1966;117(5):715-717.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

ETHACRYNIC acid, 2-3 dichloro-4-(2 methylenebutyrl) phenoxyacetic acid, has received considerable attention as a new potent diuretic. It has been found effective in treating the edema of cardiac decompensation, renal disease, and hepatic cirrhosis.^1-4 It is also useful as an antihypertensive agent.⁵

The major adverse effects of the drug are alterations in fluid and electrolyte balance,^1,2 and in some cases, orthostatic hypotension as well as hepatic coma secondary to these changes. Gastrointestinal symptoms^1-4 including nausea, vomiting, abdominal pain, and diarrhea have also been reported as have symptomatic hypoglycemia² and asymptomatic hyperuricemia.^1,2 A single case of transient acute deafness following the intravenous administration of ethacrynic acid was noted by Maher and Schreiner.²

This report documents five instances of transient hearing loss in patients receiving ethacrynic acid.

Report of Cases

CASE 1.

—Patient S. R., a 55-year-old Negro housewife with diabetes mellitus of 26 years' duration, was admitted to the New York Hospital . . . [Full Text PDF of this Article]

Author Affiliations
NEW YORK

From the Department of Medicine, The New York Hospital-Cornell Medical Center, New York.

Footnotes
Received for publication Dec 29, 1965; accepted Jan 7, 1966.

Reprint requests to 525 E 68th St, New York, NY 10021 (Dr. Becker).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?